NDAINTRAVENOUSPOWDER
Approved
Jan 2025
Lifecycle
Growth
Competitive Pressure
8/100
Clinical Trials
1
Mechanism of Action
12.1 Mechanism of Action Treosulfan is an alkylating agent. DNA alkylation is thought to be responsible for the cytotoxic activities of treosulfan. Treosulfan showed hematopoietic stem cell depleting activity as well as immunosuppressive and antitumor activity in mouse models of leukemia. 12.2…
Clinical Trials (1)
Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Started Jun 2005
60 enrolled
LeukemiaMyelodysplastic Syndromes
Loss of Exclusivity
LOE Date
Jan 21, 2030
47 months away
Patent Expiry
Oct 12, 2026
Exclusivity Expiry
Jan 21, 2032
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 7199162 | Oct 12, 2026 | U-4142 |